•TEPKINLY (epcoritamab) received EC marketing authorization as the first bispecific-based, chemotherapy-free therapy for second-line follicular lymphoma.
•Berger Montague PC announced a class action lawsuit against Hub Group on behalf of investors who acquired securities between April 28, 2023, and May 11, 2026.